Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Autoimmune Diseases Clear all
Completed No phase listed Observational

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

NCT01698515
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Jul 21, 2026, 11:11 AM EDT
Terminated No phase listed Observational

Clinical Evaluation of the TITAN™ Total Shoulder System

NCT03245320
View directory record Official record
Conditions
Arthritis, Arthritis, Degenerative, Rheumatoid Arthritis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Avascular Necrosis, Joint Instability, Joint Trauma, Dislocation, Shoulder, Pain, Shoulder
Interventions
Integra TITAN™ Total Shoulder Generation 1.0
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2Phase 3 Interventional

Lab Study of MQX-503 in Treatment of Raynaud's

NCT00253331
View directory record Official record
Conditions
Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
Interventions
topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 29, 2007 · Synced Jul 21, 2026, 11:11 AM EDT
Active, not recruiting Phase 1 Interventional

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220
View directory record Official record
Conditions
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Interventions
AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Web-based Support to Manage Arthritis Pain

NCT01463189
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Interventions
painACTION: Arthritis
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906
View directory record Official record
Conditions
Chronic Mental Illness, Chronic Physical Illness
Interventions
Patient-Directed Wellness Account, Health Navigator
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 55 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting Phase 2 Interventional

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

NCT07284641
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions
Hematopoietic stem cell transplant (HSCT)
Biological
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Not listed Phase 3 Interventional

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

NCT00577304
View directory record Official record
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease
Interventions
Nitroglycerin, Topical AmphiMatrix
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
15 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional

BEYOND Pilot Study

NCT00893217
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaseron (Interferon beta-1b, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2009 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

NCT00266669
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2007 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

NCT00001768
View directory record Official record
Conditions
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions
Intravenous immunoglobulin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional Results available

Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA

NCT00289107
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis
Interventions
Total Knee Arthroplasty, Total knee replacement
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
3
States / cities
Greensboro, North Carolina • Austin, Texas • Lakewood, Washington
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting No phase listed Observational

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT01351545
View directory record Official record
Conditions
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2041
U.S. locations
142
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 21, 2026, 11:11 AM EDT
Completed No phase listed Observational

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

NCT03670667
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 2 Interventional Results available

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

NCT00235989
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta 1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 21, 2026, 11:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

NCT05950308
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 21, 2026, 11:11 AM EDT
Active, not recruiting No phase listed Observational

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

NCT02281747
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
20 Years to 100 Years
Enrollment
521,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

NCT00856544
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
46
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jul 21, 2026, 11:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ocrelizumab for Psychosis by Autoimmunity

NCT03971487
View directory record Official record
Conditions
Schizo-Affective Type of Psychosis, Schizophrenia
Interventions
Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion
Behavioral · Diagnostic Test · Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 21, 2026, 11:11 AM EDT
Completed Not applicable Interventional

Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)

NCT02301247
View directory record Official record
Conditions
Multiple Sclerosis, Progressive, Cognition - Other, Memory Impairment
Interventions
Memory retraining exercises, Placebo control memory exercises
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
30 Years to 59 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 11:11 AM EDT